ATHE supplier map: what counterparties reveal about Alterity Therapeutics' operating posture

Alterity Therapeutics (ticker ATHE) operates as a small-cap biotech that monetizes by developing licensed therapeutic platforms and raising capital through placements and strategic financings while outsourcing non-core functions—legal, audit, investor relations, registry, and corporate advisory—to specialist providers. The company’s supplier roster signals a classic biopharma operating model: asset development internally, cost-efficient external providers for capital markets and corporate services. For diligence or underwriting, this note distills every supplier relationship surfaced in public reporting and what each counterparty implies for concentration, control, and execution risk. Learn more about structured supplier intelligence at https://nullexposure.com/.

Why these suppliers matter for investors

Capital markets and corporate-service suppliers carry disproportionate influence for a development-stage biotech: placement managers determine access to capital; registrars and auditors underpin governance and investor communications; legal counsel shapes deal execution and IP protection. Alterity's current supplier set emphasizes capital-raising capability and governance scaffolding rather than operational manufacturing or commercialization partners. That profile is consistent with a company in clinical or pre-commercial stages that funds repeat R&D through placements and licensing.

If you want to map counterparty risk across portfolio companies, visit https://nullexposure.com/ for tools and analysis.

The counterparty list — who does what, in plain English

Below I cover every named supplier reported in the available results, with a concise plain-English summary and the source for each observation.

MST Financial Services Pty Ltd (MST)

MST acted as the sole manager for a strategic placement that raised A$20.0 million in September 2025, indicating MST handled the primary capital raise execution for that financing round. According to a GlobeNewswire press release and related market reports dated September 8, 2025, MST was the exclusive placement manager for the transaction.

PricewaterhouseCoopers (PwC)

PricewaterhouseCoopers is listed as Alterity’s auditor in the company’s FY2026 filings, providing external financial assurance and reporting services from its Southbank, Victoria office. This auditor designation is recorded in the company’s SEC/6‑K disclosure in FY2026.

Gilbert + Tobin

Gilbert + Tobin is named as Alterity’s solicitors, supplying corporate and transactional legal services from their Melbourne office, as disclosed in the company’s FY2026 6‑K filing.

UniQuest

UniQuest, the University of Queensland’s commercialisation arm, granted Alterity a licence for zinc ionophore technology used to address antibiotic resistance, reflecting a technology-in licensing relationship reported in FY2020. The licensing agreement was described in a SmallCaps news article covering Alterity’s efforts to commercialize that technology.

Kemdev Pty Ltd

Kemdev Pty Ltd, identified as an associated entity of Mr Geoffrey Kempler, received A$70,514 (excl. GST) in corporate advisory fees during the half-year ended December 31, 2025—an explicit related‑party services payment documented in the FY2026 6‑K filing.

Automic Pty Ltd

Automic Pty Ltd is listed as Alterity’s share registrar, handling the share register and investor contact functions from its Perth office, per the company’s FY2026 disclosures.

Tiberend Strategic Advisors, Inc.

Tiberend Strategic Advisors functions as a media/communications contact for Alterity in multiple public releases across FY2025–FY2026, handling press and investor communications for positive data releases and shareholder letters, as noted in Yahoo Finance and other syndicated press items.

Investor Relations Advisory Solutions

Investor Relations Advisory Solutions, with Remy Bernarda listed as a contact, is reported as an investor relations provider in Alterity’s FY2025 and FY2026 public communications, indicating a retained IR relationship for U.S. investor outreach and regulatory communications.

What the supplier list reveals about operating constraints and company signals

With no explicit contractual constraints reported in the dataset, interpret the supplier roster as a set of company-level signals:

• Contracting posture — outsourced and market-facing. Alterity outsources capital markets, IR, legal, audit, and registry functions rather than building them in-house. That posture reduces fixed overhead but increases vendor dependency for execution on financings and communications.
• Concentration — moderate, centered on capital-raising partners. The single‑manager placement with MST in FY2025 highlights a concentration of capital-raising execution through one boutique manager for that transaction; repeated use of the same IR and media advisors (Tiberend, Investor Relations Advisory Solutions) indicates reliance on a small set of communications providers.
• Criticality — high for a handful of suppliers. Auditors (PwC), the share registrar (Automic), and legal counsel (Gilbert + Tobin) are critical for governance and transaction completion; related‑party payments to Kemdev introduce governance scrutiny but are modest in absolute value.
• Maturity — governance scaffolding consistent with a development-stage biotech. The mix of university licensing (UniQuest) and boutique capital markets relationships fits a company still focused on R&D and financing rather than commercial supply chains.

Key risk signal: related‑party advisory fees and a sole-manager placement structure create points of counterparty concentration and potential governance review. The supplier map does not show manufacturing or commercialization partners, reinforcing the view that material revenue drivers remain future, not current.

Investment implications and recommended follow-ups

• For investors assessing counterparty risk, prioritize confirmation of repeatability and diversity in capital-raising channels beyond the single FY2025 placement; monitor whether Alterity appoints additional banks or syndicates future placements.
• Validate independence and tenure of external auditors and legal counsel in the next 6‑K/annual reports given their governance role.
• For underwriters and operators, examine the UniQuest licence for IP scope and milestone structure to assess upside and liability exposure.

If you want a tailored review of ATHE’s supplier exposures or a custom counterparty-risk score, start here: https://nullexposure.com/.

Bottom line

Alterity’s supplier set is compact and market-facing: capital markets execution, investor communications, and governance services dominate. That configuration is appropriate for a development-stage biopharma but creates concentration and reliance on a few external providers for funding, messaging, and compliance. Investors should track whether the company diversifies its placement managers and discloses any changes to related-party advisory arrangements to reduce single-counterparty risk. For deeper supplier mapping and continuous monitoring, visit https://nullexposure.com/.